MannKind stock falls 4.70 percent to USD 3.04 on Nasdaq October 16, 2026
Published on 10/17/2026 at 21:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPrice move and quarterly growth
- MannKind stock fell on Nasdaq on October 16, 2026.
- Second-quarter revenue rose 43.00 percent year over year to USD 109.37 million.
- MannKind stock cost USD 3.04 at Nasdaq on October 16, 2026, down 4.70 percent versus the prior close.
- MannKind had a market capitalization of USD 977.5 million as of October 16, 2026.
MannKind stock fell 4.70 percent to USD 3.04 on Nasdaq on October 16, 2026, compared with a prior close of USD 3.19. The move came as the stock remained well above its 52-week low but below its yearly high.
Quarterly revenue reached USD 109.37 million
MarketBeat reported that MannKind generated USD 109.37 million in revenue in the second quarter of 2026, up 43.00 percent from the same quarter of 2025. Adjusted earnings per share were negative USD 0.01, matching the consensus estimate, while the GAAP net loss was USD 19.03 million.
The revenue growth gives the market a stronger operating reference than the headline move alone. Cash and cash equivalents stood at USD 52.93 million at the end of the second quarter, while operating cash flow was negative USD 18.37 million in that quarter.
Stock remains below its yearly high
MannKind traded between USD 3.02 and USD 3.24 on October 16, 2026, with volume of 2,605,091 shares against an average volume of 4,531,382 shares. The session range therefore covered USD 0.22, while the closing price was USD 0.02 above the low.
The 52-week range was USD 2.23 to USD 6.51 as of October 16, 2026. The stock stood 36.32 percent above the low and 53.30 percent below the high. The closing price was also below the 50-day moving average of USD 3.82 cited by MarketBeat.
Valuation and company calendar
MannKind had a market capitalization of USD 977.5 million as of October 16, 2026. Its trailing price-to-earnings ratio was negative 22.14, reflecting the company's reported loss, and its dividend yield was 0.00 percent.
MannKind's investor-relations page identifies Nasdaq as its primary exchange and MNKD as its ticker. The company describes its business as focused on inhaled treatments for endocrine and orphan lung diseases, including Afrezza and other dry-powder therapies. Its investor calendar listed participation in the Chardan Healthcare Conference on October 14, 2026.
Comparison with peers
MannKind (Nasdaq, USD): minus 4.70 percent, P/E negative 22.14, market capitalization USD 977.5 million.
Thermo Fisher Scientific (NYSE, USD): minus 0.93 percent, P/E 37.12, market capitalization USD 255.1 billion.
United Therapeutics (Nasdaq, USD): minus 1.55 percent, P/E 19.10, market capitalization USD 22.9 billion.
Price and market position
The Nasdaq session placed MannKind close to the lower end of its daily range and well below its 52-week high. The revenue increase in the second quarter contrasts with the continuing net loss and negative operating cash flow, leaving the next reported period important for judging whether growth is translating into better cash generation.
MannKind stock cost USD 3.04 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.70 percent versus the prior close of USD 3.19.
Market context: Market report Nasdaq Composite.
